July 07, 2025
A Quebec man who has spent years fighting for access to a promising prostate cancer treatment says he was overcome with emotion when the province finally approved it last week.
Jean Krashevski was first diagnosed with aggressive prostate cancer in 2015. After surgery and 33 rounds of radiation, he hoped the disease was behind him. But within a year and a half, it returned — this time spreading to other parts of his body, including his brain.
“I should be dead by now,” he said. “But we moved quickly, and we fought hard. This new treatment gives us something we haven’t had in a long time: hope.”
Pluvicto, the drug for this treatment, is a radiopharmaceutical therapy that delivers targeted radiation directly to prostate cancer cells. It’s designed for patients with metastatic castration-resistant prostate cancer who have already undergone hormone therapy and chemotherapy. On July 2, the Quebec government added it to the province’s list of publicly covered medications.
For Krashevski, who launched a petition a year ago demanding the province fund Pluvicto, it was a long-awaited breakthrough.